Table 3.
Outcome measures.
| Outcome | Study | Participants | Results | ||
|---|---|---|---|---|---|
| Baseline | Posttesting | % change | |||
| Cure rate (no. of patients) | Mullane et al. 2013 [32] | Fidaxomycin stage 3 CKD | 112 | 89 | 79.5 |
| Fidaxomycin stage 4 CKD | 46 | 34 | 73.9 | ||
| Vancomycin stage 3 CKD | 113 | 91 | 80.5 | ||
| Vancomycin stage 4 CKD | 50 | 38 | 76.0 | ||
| Cammarota et al. 2015 [33] | FMT | 20 | 18 | 90.0 | |
| Vancomycin | 19 | 12 | 63.2 | ||
| Lackowicz et al. 2014 [30] | Nephrology ward patients | 9 | 4 | 44.4 | |
| Kujawa et al. 2015 [29] | LP299v | 21 | 19 | 90.4 | |
| Recurrence (no. of patients) | Mullane et al. 2013 [32] | Fidaxomycin stage 3 CKD | 89 | 19 | 21.4 |
| Fidaxomycin stage 4 CKD | 34 | 5 | 14.7 | ||
| Vancomycin stage 3 CKD | 91 | 30 | 33.0 | ||
| Vancomycin stage 4 CKD | 38 | 12 | 31.6 | ||
| Lackowicz et al. 2014 [30] | Nephrology ward patients | 4 | 3 | 75.0 | |
| Cammarota et al. 2015 [33] | FMT | 18 | 2 | 11.1 | |
| Vancomycin | 17 | 12 | 70.5 | ||
| Kujawa et al. 2015 [29] | LP299v | 21 | 2 | 9.0 | |
| Mortality (no. of patients) | Mullane et al. 2013 [32] | Stage 3 CKD | — | — | — |
| Stage 4 CKD | — | — | — | ||
| Lackowicz et al. 2014 [30] | Nephrology ward patients | 9 | 2 | 22 | |
| Cammarota et al. 2015 [33] | FMT | 20 | 2 | 10 | |
| Vancomycin | 19 | 6 | 31.5 | ||
| Duration of diarrhea (days) | Kujawa et al. 2015 [29] | LP299v in the patients with recurrence (n = 2) | 28 | 9.5 | 33.9 |
| Number of stools per day | Kujawa et al. 2015 [29] | LP299v in the patients with recurrence (n = 2) | 8 | 7 | — |
| Average CRP serum concentration (mg/l) | Kujawa et al. 2015 [29] | LP299v in the patients with recurrence (n = 2) | 96.5 | 43.8 | |